Amneal Pharmaceuticals (AMRX) vs Belite Bio (BLTE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Belite Bio (BLTE) has outperformed Amneal Pharmaceuticals (AMRX) over the past year, gaining 100.9% versus a gain of 89.7%. Amneal Pharmaceuticals is the larger company by market cap ($6.84 billion vs $6.29 billion), about 1.1 times the size. On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (16.5x vs 69.1x for Belite Bio).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | BLTE |
|---|---|---|
| Share price | $19.65 | $156.08 |
| Market cap | $6.84B | $6.29B |
| 1-day change | -3.18% | +0.30% |
| YTD return | +55.95% | -2.79% |
| 1-year return | +89.67% | +100.90% |
| 5-year return | +248.40% | — |
| P/E ratio (TTM) | 40.10 | — |
| Forward P/E | 16.48 | 69.06 |
| EPS (TTM) | $0.49 | $-2.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | — |
| Revenue growth (YoY) | +8.05% | — |
| Net income (latest FY) | $72.06M | $-77.61M |
| Gross margin | 36.88% | — |
| Operating margin | 13.05% | — |
| Net margin | 2.39% | — |
| 52-week high | $21.18 | $200.00 |
| 52-week low | $9.56 | $76.50 |
| Distance from 52-week high | -7.20% | -21.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +15.57% | +46.65% |
| Average volume | 2.22M | 182.25K |
| Shares outstanding | 348.30M | 40.27M |
| Employees | 8,700 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed AMRX by 11.2 percentage points over the past year.
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
AMRX vs BLTE FAQ
Which is bigger, Amneal Pharmaceuticals or Belite Bio?
Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $6.84B compared with $6.29B for Belite Bio (BLTE).
Which stock has performed better over the past year, AMRX or BLTE?
BLTE returned +100.90% over the past 12 months, compared with +89.67% for AMRX (price return, excluding dividends). Past performance does not predict future results.
Are Amneal Pharmaceuticals and Belite Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.